Advertisement

Search Results

Advertisement



Your search for early matches 10011 pages

Showing 551 - 600


A Look Back on an Impactful and Inspiring Presidential Year

Serving as ASCO’s 60th President over the past year has been an honor and a privilege, said Lynn M. Schuchter, MD, FASCO, who will end her Presidential term during ASCO’s Annual Meeting, being held from May 31 to June 4, 2024, in Chicago, and welcome incoming President Robin Zon, MD, FACP, FASCO,...

global cancer care

We Have an IDEA: United in the Fight Against Cancer

On behalf of 2024 International Development and Education Award (IDEA) awardees, we received the decision of our acceptance in this outstanding training program offering mentorship and educational opportunities for early-career oncologists and cancer researchers with great interest. This will...

supportive care

Dance/Movement Therapy for Pediatric Oncology Patients and Their Caregivers

Guest Editor’s Note: Children with cancer and their caregivers face physical and psychosocial challenges during and after treatment. Dance/movement therapy has been used to improve well-being, promote healthy coping, and mitigate the impact of illness, but limited knowledge exists regarding its...

gynecologic cancers

Noninferiority of Simple vs Radical Hysterectomy for Pelvic Recurrence in Low-Risk Cervical Cancer

As reported in The New England Journal of Medicine by Marie Plante, MD, of Centre Hospitalier Universitaire de Quebec, and colleagues, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in the frequency of pelvic recurrence in women with low-risk cervical...

lung cancer

Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall survival with the tyrosine kinase inhibitor atezolizumab (multiple targets, including MET, AXL, VEGFR2, RET, and FLT) plus the...

breast cancer

USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer

On April 30, 2024, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer.1 The USPSTF now recommends that all women undergo screening for breast cancer every other year starting at age 40 and continuing through age 74. More...

breast cancer

Novel Approaches Show Early Activity in Endocrine-Resistant Breast Cancer

For breast cancer that is estrogen receptor–positive, CDK4/6 inhibitors, given with endocrine therapy, have become the standard of care, especially in metastatic disease. However, resistance to both endocrine therapies and CDK4/6 inhibitors is common, and new approaches are needed to counteract...

issues in oncology

HPV Vaccine Shows Prevention Efficacy for Several Types of HPV-Related Cancers in Both Males and Females

According to the Centers for Disease Control and Prevention, since the human papillomavirus (HPV) vaccine was introduced in the United States in 2006, HPV infections that cause most HPV-related cancers and genital warts have decreased by 88% among teenage girls and 81% among young adult women. Now, ...

breast cancer

Use of Topical Diclofenac Gel to Prevent Capecitabine-Associated Hand-Foot Syndrome

In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that the nonsteroidal, anti-inflammatory topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast ...

kidney cancer
immunotherapy

CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma

Evidence from a small early trial called COBALT-RCC provides proof of concept for use of an allogeneic off-the-shelf CD70-targeted chimeric antigen receptor (CAR) T-cell therapy called CTX130 in patients with advanced clear cell renal cell carcinoma (RCC). CTX130 is engineered using gene-editing...

issues in oncology

Study Finds the Financial Hardship Caused by Cancer Is Long-Lasting for Many Working-Age Adults

When combined with high out-of-pocket costs for cancer care, nearly 60% of working-age cancer survivors report experiencing at least one type of financial hardship, including being unable to afford medical bills, distress and worry, or delaying or forgoing needed care because of cost, according to...

hepatobiliary cancer

Gallbladder Cancer Rates Among Black Patients in the United States

Gallbladder cancer rates have been stable or declining for most Americans over the past two decades, but cases have steadily risen among Black Americans, with growing numbers of cases not being diagnosed until later disease stages, according to a study presented at Digestive Disease Week 2024...

multiple myeloma
breast cancer
bladder cancer
gynecologic cancers
skin cancer
pancreatic cancer

NCCN Clinical Practice Guidelines in Oncology: 2024 Updates

The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...

solid tumors
issues in oncology

End-of-Life Systemic Therapy May Not Improve Survival in Patients With Advanced Solid Tumors

Systemic therapy may offer no significant improvement in overall survival in patients with advanced solid tumors, according to a recent study published by Canavan et al in JAMA Oncology. Study Methods and Results In the recent study, the investigators analyzed the de-identified data of over 78,000...

Daniel M. Geynisman, MD, Named New JNCCN Editor-in-Chief

Daniel M. Geynisman, MD, has been announced as the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman is Associate Professor in the Department of Hematology/Medical Oncology and Chief of the Division of Genitourinary Medical Oncology at Fox Chase...

lymphoma

Early Relapsed/Refractory DLBCL

This is Part 1 of Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Jason Westin, Dai Chihara, and Caron A. Jacobson discuss the treatment of early...

issues in oncology

AACR Cancer Disparities Progress Report 2024 Highlights Ongoing Health Inequities Experienced by Racial and Ethnic Minorities

Despite the extraordinary progress against cancer in the United States—illustrated by the continuing decline in the overall mortality rate, which fell by 33% between 1991 and 2020, and the increasing numbers of cancer survivors (over 18 million and climbing)—the burden of cancer remains...

gynecologic cancers
head and neck cancer
colorectal cancer

FDA Approves HPV Self-Collection Solution

On May 15, Roche announced the U.S. Food and Drug Administration (FDA) approval of its human papillomavirus (HPV) self-collection solution—one of the first of such tests available in the United States. Screening for HPV can help identify women who are at risk of developing cervical cancer so that...

skin cancer
issues in oncology

Disparities in Melanoma Outcomes Among Black Patients

Investigators may have uncovered sex-based disparities in the detection and survival of melanoma in Black patients, according to a recent study published by Steadman et al in the Journal of Surgical Oncology. Background Melanoma is an aggressive type of skin cancer that accounts for about 75% of...

breast cancer
geriatric oncology
issues in oncology

Chemotherapy May Accelerate Physical Decline in Older Patients With Early-Stage Breast Cancer

Investigators have found that female patients aged 65 years or older with high-risk breast cancer who are treated with chemotherapy may be more likely to experience a substantial decline in physical function, according to a recent study published by Sedrak et al in the Journal of Cancer...

breast cancer
geriatric oncology

Study Reveals Potential Overtreatment of DCIS in Older Women With Limited Life Expectancy

Ductal carcinoma in situ (DCIS) may often be overtreated in older women with limited life expectancy, according to research presented during the 2024 Society of Surgical Oncology (SSO) Annual Meeting.1 The retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare...

colorectal cancer
issues in oncology

Colorectal Cancer Incidence Is Rising Among Teenagers and Young Adults

The incidence of colorectal cancer has risen significantly among younger U.S. patients over the past 2 decades, according to new findings presented by Mohamed et al at Digestive Disease Week (DDW) 2024 (Abstract Mo1149) and simultaneously published in Gastroenterology. Background “Colorectal cancer ...

gastroesophageal cancer
supportive care

Oral Rinse Could Provide Early Screening for Gastric Cancer

A simple oral rinse may lead to early detection of gastric cancer, according to new findings presented by Perati et al at Digestive Disease Week (DDW) 2024 (Abstract 949) and simultaneously published in Gastroenterology. Background Gastric cancer is the fourth leading cause of cancer mortality...

NIH’s New Cancer Screening Research Network and Cancer Screening Technologies

The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...

immunotherapy

KEYNOTE-756 Additional Findings: Pembrolizumab Shown to Be Beneficial Regardless of Age, Menopausal Status

In updated findings from the phase III KEYNOTE-756 trial, the addition of pembrolizumab to chemotherapy in the neoadjuvant setting improved the rates of pathologic complete response for patients with high-risk estrogen receptor–positive, HER2-negative breast cancer, regardless of their age or...

issues in oncology

AI in Cancer Care: Embrace the Change

According to Google Chief Executive Officer Sunder Pichai, artificial intelligence (AI) is “the most profound technology humanity is working on—more profound than fire or electricity or anything that we’ve done in the past.” The impact of AI on health care and especially cancer care will not be...

issues in oncology

ASCO Survey Finds Oncologists’ Well-Being Worsened Over the Past Decade—but Steps Can Be Taken to Mitigate Burnout

A recent survey by ASCO measuring postpandemic burnout among oncologists in the United States shows that professional satisfaction and work-life balance have significantly deteriorated over the past decade, with 59% of respondents reporting one or more symptoms of burnout, compared with 34% in...

head and neck cancer

Two Studies Support Deintensification of Treatment for HPV-Associated Oropharyngeal Cancer

Two studies presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium added support for the deintensification of radiotherapy in early-stage oropharyngeal squamous cell cancers associated with the human papillomavirus (HPV), a subtype typically more responsive to therapy compared to...

breast cancer

Selective Targeting of PARP1 in Early-Phase Study Shows Activity in Breast Cancer

Saruparib, a first-in-class PARP1-­selective inhibitor, was reported to have favorable safety and anticancer activity in heavily pretreated patients with breast cancer harboring homologous recombination–repair (HRR) mutations, according to the results of the phase I/II PETRA study presented at the...

gynecologic cancers

For Detection of Measurable Residual Disease in Ovarian Cancer, Are Two Methods Better Than One?

In patients with ovarian cancer, second-look surgery may find a role again. The evaluation of measurable residual disease (MRD) using second-look laparoscopy identified more women who had detectable MRD after front-line treatment than did circulating tumor DNA (ctDNA), according to a study...

breast cancer
genomics/genetics

Breast-Conserving Therapy in BRCA-Mutation Carriers: Study Looks at Long-Term Outcomes

Recent research has provided valuable insights into the long-term outcomes of patients with pathogenic BRCA1 and BRCA2 mutations who undergo breast-conserving therapy, according to a study presented at the 2024 Society of Surgical Oncology (SSO) Annual Meeting.1 The observational study found that...

solid tumors
issues in oncology
supportive care

AI Model May Accurately Predict Mental Health Outcomes in Patients With Cancer

A novel artificial intelligence (AI) model may accurately predict which patients with cancer may require mental health services during cancer care, according to a recent study published by Nunez et al in Communications Medicine. Background Mental health has been shown to have a significant impact...

lung cancer
issues in oncology

Smoking Cessation Regimens: Does Dose of Therapy Matter?

Altering or increasing the dosages of smoking cessation regimens may help patients quit smoking, according to a recent study published by Cinciripini et al in JAMA. The findings indicated that the smoking cessation drug varenicline may be more effective than combined nicotine replacement therapy...

prostate cancer
supportive care
issues in oncology

Effect of Mindfulness Audio Recordings on Physical, Emotional Side Effects During Radiation Therapy for Prostate Cancer

Listening to mindfulness audio recordings may effectively alleviate the side effects of radiation therapy in men with prostate cancer, according to a recent study published by Victorson et al in Global Advances in Integrative Medicine and Health. Background Men with prostate cancer who receive...

solid tumors
issues in oncology

Mortality Trends Among Asian American, Native Hawaiian, and Other Pacific Islander Patients With Preventable Cancers

The American Cancer Society (ACS) has detailed disparities in the mortality rates for preventable cancer types among Asian American, Native Hawaiian, and other Pacific Islander patients in a new Cancer Facts & Figures report published by Wagle et al. Background In this report, the Asian...

prostate cancer

Metastatic Castration-Resistant Prostate Cancer: Addition of LuPSMA to Enzalutamide

In an interim analysis of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved prostate-specific antigen (PSA) progression-free survival in the first-line treatment of patients...

leukemia

Pediatric AML: Comparison of Induction Regimens

In the phase III AML2012 trial, which had early termination of enrollment and results of which were reported in the Journal of Clinical Oncology, Tierens et al found that mitoxantrone-based induction resulted in better outcomes vs liposomal daunorubicin–based induction in pediatric patients with...

lung cancer

Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC

In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associated with improved event-free survival and pathologic complete response compared with neoadjuvant chemotherapy alone in patients with early-stage non–small cell...

breast cancer

MRI-Guided Duration of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

In a Dutch phase II study (TRAIN-3) reported in The Lancet Oncology, Anna van der Voort, MD, and colleagues found that magnetic resonance imaging (MRI) detected complete radiologic response after only three cycles of neoadjuvant chemotherapy in many patients with stage II to III HER2-positive...

breast cancer

Rapid Guideline Update Supports Capivasertib for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer now have a new medication option that extends survival, according to an ASCO rapid guideline update.1 The update was designed to orient clinicians to outcomes from the CAPItello-291 trial, which led to the U.S. Food...

gynecologic cancers

Activity Shown for Antibody-Drug Conjugates in Gynecologic Cancers

The recent approval of mirvetuximab soravtansine-gynx is a testament to the emerging benefit of antibody-drug conjugates in recurrent ovarian cancer. Other agents of this class are now eliciting excitement as they demonstrate high response rates in a population with unmet clinical needs, according...

head and neck cancer

Expert Point of View: Glenn J. Hanna, MD

Glenn J. Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program), medical oncologist at the Center for Head & Neck Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School, Boston, was interviewed for his...

head and neck cancer

Can HPV Circulating Tumor DNA Guide Adjuvant Treatment of Oropharyngeal Cancer?

Although so-called liquid biopsies are now helping to determine the need for adjuvant therapy for a number of malignancies, oropharyngeal carcinoma is not yet one of them, according to a prospective pilot study from Memorial Sloan Kettering Cancer Center. The investigators evaluated the use of...

gynecologic cancers

AI Analysis of Cell-Free DNA Fragments and Protein Biomarkers for Noninvasive Detection of Ovarian Cancer

A blood-based, machine learning assay that combines cell-free DNA (cfDNA) fragmentomes and protein biomarkers was able to differentiate patients with ovarian cancer from healthy controls at a high specificity of more than 99%, according to study results by Medina et al.1 It noninvasively recognized ...

breast cancer

Breast Cancer Stalked My Family for Generations and Finally Came for Me

My maternal grandmother, mother, and two of my mother’s sisters were all diagnosed with breast cancer when they were relatively young, so I figured one day, the disease would come for me. Breast cancer is the most common cancer diagnosed among Alaska Native women,1 and at a very early age, my...

covid-19

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

In a UK-based prospective cohort study reported in The Lancet Oncology, Turtle et al found that among patients hospitalized due to COVID-19 infection, those receiving cancer treatment had a higher rate of in-hospital mortality vs those without a cancer diagnosis. Study Details The study included...

gynecologic cancers
issues in oncology

Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis

Researchers have found that spatial tissue analysis may help predict early posttreatment relapse and illuminate new potential therapies in patients with high-grade serous ovarian carcinoma, according to a recent study published by Xu et al in Science Advances.   Background Many patients with...

prostate cancer
issues in oncology

Chemohormonal Therapy for Locally Advanced Prostate Cancer

A neoadjuvant chemohormonal therapy combination may offer extended control of prostate-specific antigen (PSA) levels in patients with locally advanced prostate cancer compared with hormonal therapy alone, according to a recent study published by Qian et al in The Journal of Urology. Background...

lymphoma

Relapsed Follicular Lymphoma With POD-24

This is Part 2 of Treatment Options for Relapsed/Refractory Follicular Lymphoma: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Andrew M. Evens, L. Elizabeth Budde, and Carla Casulo discuss the management of...

colorectal cancer
issues in oncology

Propofol-Based Anesthesia May Offer Improved Detection of Serrated Polyps During Colonoscopy

Deeper sedation with the anesthetic drug propofol may improve detection of serrated polyps in patients undergoing colonoscopy to screen for colorectal cancer, according to a recent study published by Quaye et al in Anesthesiology. Background Nearly all colorectal cancers start as polyps....

Advertisement

Advertisement




Advertisement